Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Anthem Inc. CORP UNIT 050118
ANTX | US
3.14
USD-0.12
-3.68%
ANTX | US
About Anthem Inc. CORP UNIT 050118
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
3.14
Open
3.25
High
3.25
Low
3.03
AN2 Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on developing treatments for rare chronic and serious infectious diseases. It is developing epetraborole which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park California.
View LessANTX | US
Risk
83.1
Sharpe
1.05
Luna's Score
46/100
Recommendation
Hold
Luna says (ANTX | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
78.9%1 month
83.1%3 months
236.6%6 months
175.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.32
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-2.11
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
93.71M
MarketCap(USD)
93.71M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-69.48
Short ratio
0.75
Short perc.
0.98
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.68
Range1M
2.32
Range3M
5.91
Volumes: Market Activity
Rel. volume
0.79
Price X volume
983.86K
